Dianthus Therapeutics, Inc. (DNTH) stock
DNTHNasdaqPharmaceutical PreparationsFiscal year ends December 31
$92.48+3.18 (+3.56%)
Close on Nov 12, 2026Market cap $5.17BP/E –Yield 0.00%
Dianthus Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Dianthus Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $188.71M, up 68.3% year over year. For fiscal 2025 it was $145.64M, up 75.2% from the year before. The highest annual figure on record is $145.64M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $145.64M | +75.2% |
| FY2024 | Dec 31, 2024 | $83.11M | +153.1% |
| FY2023 | Dec 31, 2023 | $32.84M | +11.8% |
| FY2022 | Dec 31, 2022 | $29.38M | -37.2% |
| FY2021 | Dec 31, 2021 | $46.77M | -7.6% |
| FY2020 | Dec 31, 2020 | $50.62M | -14.5% |
| FY2019 | Dec 31, 2019 | $59.21M | +43.2% |
| FY2018 | Dec 31, 2018 | $41.34M | +48.2% |
| FY2017 | Dec 31, 2017 | $27.90M | +382.5% |
| FY2016 | Dec 31, 2016 | $5.78M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $45.60M | +40.4% |
| Q2 FY2026 | Jun 30, 2026 | $48.69M | +85.5% |
| Q1 FY2026 | Mar 31, 2026 | $34.53M | +27.9% |
| Q4 FY2025 | Dec 31, 2025 | $59.90M | +126.8% |
| Q3 FY2025 | Sep 30, 2025 | $32.49M | +27.2% |
| Q2 FY2025 | Jun 30, 2025 | $26.25M | +45.3% |
| Q1 FY2025 | Mar 31, 2025 | $27.00M | +106.5% |
| Q4 FY2024 | Dec 31, 2024 | $26.41M | +200.8% |
| Q3 FY2024 | Sep 30, 2024 | $25.54M | +220.9% |
| Q2 FY2024 | Jun 30, 2024 | $18.07M | +76.2% |
| Q1 FY2024 | Mar 31, 2024 | $13.08M | +123.7% |
| Q4 FY2023 | Dec 31, 2023 | $8.78M | -10.7% |
| Q3 FY2023 | Sep 30, 2023 | $7.96M | +10.3% |
| Q2 FY2023 | Jun 30, 2023 | $10.25M | -11.6% |
| Q1 FY2023 | Mar 31, 2023 | $5.85M | -64.7% |
| Q4 FY2022 | Dec 31, 2022 | $9.83M | -25.0% |
| Q3 FY2022 | Sep 30, 2022 | $7.22M | -33.1% |
| Q2 FY2022 | Jun 30, 2022 | $11.60M | +4.3% |
| Q1 FY2022 | Mar 31, 2022 | $16.55M | +41.1% |
| Q4 FY2021 | Dec 31, 2021 | $13.11M | +7.0% |
| Q3 FY2021 | Sep 30, 2021 | $10.80M | -8.4% |
| Q2 FY2021 | Jun 30, 2021 | $11.13M | -11.7% |
| Q1 FY2021 | Mar 31, 2021 | $11.73M | -16.0% |
| Q4 FY2020 | Dec 31, 2020 | $12.26M | -34.5% |
| Q3 FY2020 | Sep 30, 2020 | $11.79M | -28.7% |
| Q2 FY2020 | Jun 30, 2020 | $12.61M | -6.1% |
| Q1 FY2020 | Mar 31, 2020 | $13.96M | +32.5% |
| Q4 FY2019 | Dec 31, 2019 | $18.71M | +51.0% |
| Q3 FY2019 | Sep 30, 2019 | $16.52M | +44.7% |
| Q2 FY2019 | Jun 30, 2019 | $13.43M | +38.7% |
| Q1 FY2019 | Mar 31, 2019 | $10.54M | +34.2% |
| Q4 FY2018 | Dec 31, 2018 | $12.39M | +123.2% |
| Q3 FY2018 | Sep 30, 2018 | $11.42M | +119.2% |
| Q2 FY2018 | Jun 30, 2018 | $9.68M | -29.9% |
| Q1 FY2018 | Mar 31, 2018 | $7.85M | – |
| Q4 FY2017 | Dec 31, 2017 | $5.55M | – |
| Q3 FY2017 | Sep 30, 2017 | $5.21M | – |
| Q2 FY2017 | Jun 30, 2017 | $13.82M | – |
See a number that looks wrong?